Putting the patient at the centre of cancer-associated thrombosis treatment decisions

Dual mTOR inhibition effective in reducing tumour load in CLL

Positive results in phase II study of copanlisib treating NHL and CLL

Prevention of gynaecological cancers: in memory of Mario Sideri

Inside cancer - public lecture

Investigational immunotherapy drug combo safe with early signs of effectiveness in advanced melanoma

Pembrolizumab showed clinical benefit in malignant pleural mesothelioma

New approaches in computational pathology for risk assessment in benign breast diseases

Chk1 inhibition combined with standard dose gemcitabine may be safe and effective

Updated results on phase III CLL trial shows 90% response rate using ibrutinib

Latest trials and outcomes with new CLL treatments

Developing treatments for indolent non hodgkin lymphoma